Key result
Alteplase and streptokinase demonstrated similar clinical and instrumental efficacy in the treatment of high- and intermediate-to-high risk pulmonary artery thromboembolism.
Why the study?
Does alteplase improve clinical and instrumental efficacy compared to streptokinase in patients with high- and intermediate-to-high risk pulmonary embolism?
Observational (n=40)
Does alteplase improve clinical and instrumental efficacy compared to streptokinase in patients with high- and intermediate-to-high risk pulmonary embolism?
In a small retrospective cohort, alteplase and streptokinase demonstrated similar clinical and instrumental efficacy in the treatment of high- and intermediate-to-high risk pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Similar efficacy seen in retrospective PE data; leaves open agent preference and requires randomized confirmation before practice change.
The authors carried out a retrospective analysis of clinical efficacy of streptokinase and alteplase (actilyse®) in patients presenting with high- and intermediate-to-high risk pulmonary artery thromboembolism (PATE) who were discharged from hospital after appropriate treatment performed. Of the total number of the treated patients, we formed 2 groups comprising 20 patients each, receiving alteplase (group 1) and streptokinase (group 2). The patients were comparable by the main clinical characteristics, predisposing factors, severity of pulmonary artery thromboembolism (PATE) and duration of treatment. Efficacy of thrombolytic therapy assessed clinically and instrumentally did not differ. However, by the stratified risk and frequency of PATE relapses, the condition of patients receiving alteplase turned out to be more severe. Based on the obtained results, a conclusion was made that actilyse is a drug of choice for treatment of patients with PATE.
No takes yet. Share an insight, caveat, or question.
Хорев et al. (2019) conducted an observational in High- and intermediate-to-high risk pulmonary artery thromboembolism (PATE) (n=40). Alteplase vs. Streptokinase was evaluated on Clinical and instrumental efficacy. Alteplase and streptokinase demonstrated similar clinical and instrumental efficacy in the treatment of high- and intermediate-to-high risk pulmonary artery thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: